Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 411-420 of 2762 for

Edit search filters
  1. S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

    Mankato, MN

  2. Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

  4. A Study of Cemiplimab in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

    Scottsdale/Phoenix, AZ

  5. EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  6. Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

    Rochester, MN

  7. Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer

    Jacksonville, FL

  8. A Study of XmAb ®18087 in Subjects With NET and GIST

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer

    Rochester, MN

.

Mayo Clinic Footer